$GH
Guardant Health, Inc. Stock $gh

$gh Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000157628024000261 Filed on November 06, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$191.5M
YoY Change		33.87%
Cost Of Revenue		$74.49M
YoY Change		29.32%
Gross Profit		$117.0M
YoY Change		36.99%
Gross Profit Margin		61.1%
Selling, General & Admin		$147.0M
YoY Change		39.86%
% of Gross Profit		125.66%
Research & Development		$87.31M
YoY Change		-6.97%
% of Gross Profit		74.63%
Depreciation & Amortization		$10.10M
YoY Change		-1.94%
% of Gross Profit		8.63%
Operating Expenses		$234.3M
YoY Change		17.77%
Operating Profit		-$117.3M
YoY Change		3.33%
Interest Expense		$13.81M
YoY Change		2044.57%
% of Operating Profit
Other Income/Expense, Net		-$3.007M
YoY Change		-117.81%
Pretax Income		-$107.7M
YoY Change		25.83%
Income Tax		$30.00K
% Of Pretax Income
Net Earnings		-$107.8M
YoY Change		25.15%
Net Earnings / Revenue		-56.28%
Basic Earnings Per Share		-$0.88
Diluted Earnings Per Share		-$0.88
COMMON SHARES
Basic Shares Outstanding	123.6M shares	123.0M shares
Diluted Shares Outstanding		123.1M shares

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$895.7M
YoY Change		-22.44%
Cash & Equivalents		$585.0M
Short-Term Investments		$310.7M
Other Short-Term Assets		$170.2M
YoY Change		549.73%
Inventory		$72.30M
Prepaid Expenses
Receivables		$88.47M
Other Receivables		$0.00
Total Short-Term Assets		$1.227B
YoY Change		-8.92%
LONG-TERM ASSETS
Property, Plant & Equipment		$125.2M
YoY Change		-15.24%
Goodwill		$3.290M
YoY Change		0.0%
Intangibles		$7.251M
YoY Change		-25.02%
Long-Term Investments
YoY Change
Other Assets		$31.34M
YoY Change		-75.52%
Total Long-Term Assets		$312.0M
YoY Change		-30.72%
TOTAL ASSETS
Total Short-Term Assets		$1.227B
Total Long-Term Assets		$312.0M
Total Assets		$1.539B
YoY Change		-14.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$15.47M
YoY Change		-80.12%
Accrued Expenses		$71.67M
YoY Change		-65.08%
Deferred Revenue		$29.55M
YoY Change		37.56%
Short-Term Debt		$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities		$197.3M
YoY Change		-12.97%
LONG-TERM LIABILITIES
Long-Term Debt		$1.142B
YoY Change		0.23%
Other Long-Term Liabilities		$89.45M
YoY Change		778.47%
Total Long-Term Liabilities		$89.45M
YoY Change		778.47%
TOTAL LIABILITIES
Total Short-Term Liabilities		$197.3M
Total Long-Term Liabilities		$89.45M
Total Liabilities		$1.599B
YoY Change		1.91%
SHAREHOLDERS EQUITY
Retained Earnings		-$2.467B
YoY Change		26.21%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		-$60.10M
YoY Change
Total Liabilities & Shareholders Equity		$1.539B
YoY Change		-14.38%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$107.8M
YoY Change		25.15%
Depreciation, Depletion And Amortization		$10.10M
YoY Change		-1.94%
Cash From Operating Activities		-$51.06M
YoY Change		-34.36%
INVESTING ACTIVITIES
Capital Expenditures		$4.199M
YoY Change		77.17%
Acquisitions
YoY Change
Other Investing Activities		-$290.6M
YoY Change		-210.47%
Cash From Investing Activities		-$294.8M
YoY Change		-213.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-2.885M
YoY Change		-175.72%
NET CHANGE
Cash From Operating Activities		-51.06M
Cash From Investing Activities		-294.8M
Cash From Financing Activities		-2.885M
Net Change In Cash		-348.8M
YoY Change		-286.79%
FREE CASH FLOW
Cash From Operating Activities		-$51.06M
Capital Expenditures		$4.199M
Free Cash Flow		-$55.26M
YoY Change		-31.07%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001576280
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Registrant Name EntityRegistrantName	GUARDANT HEALTH, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	66883000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	27741000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	1226715000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1347106000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	125169000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	145096000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	144964000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	157616000	usd
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	7251000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8979000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	3290000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3290000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	31338000	usd
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.66
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.66
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	123051000	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	123051000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	122406000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	122406000	shares
	us-gaap	Profit Loss ProfitLoss	-292406000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	456000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	3315000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	466000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	15783000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1900000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-526000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-75000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1941000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2356000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2789000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	391000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	13842000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-105398000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-83313000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-324976000	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-278564000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-1613000	usd
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	123554612	shares
CY2024Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	310701000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	35097000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	88465000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	88783000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	72298000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	61948000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	124334000	usd
CY2024Q3	us-gaap	Assets Assets	1538727000	usd
CY2023Q4	us-gaap	Assets Assets	1786421000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-107724000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-291180000	usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	490000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	568000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1226000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-107754000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-86102000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-325367000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-292406000	usd
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.66
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.66
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	117736000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	117736000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	109791000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109791000	shares
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-107754000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-86102000	usd
	us-gaap	Profit Loss ProfitLoss	-325367000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	20000	usd
CY2024Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2874000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	49769000	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2356000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-107754000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-60096000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	292726000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	70000	usd
CY2023Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3003000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21819000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	60180000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	260172000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	216100000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	36174000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	128243000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	118135000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	776108000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-317629000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-367214000	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	11690000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	42038000	usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3007000	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	16885000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-85612000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-324799000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-292406000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	104045000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1935000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1931000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2815000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	10913000	usd
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	688368000	usd
CY2023Q4	gh	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Excluding Other Assets CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsExcludingOtherAssets	1133537000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	15473000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	51741000	usd
CY2024Q3	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2023Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	123158418	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	123158418	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	121629861	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	121629861	shares
CY2024Q3	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	usd
CY2023Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	1000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2410416000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2304220000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3284000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3675000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2467229000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2141862000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-60096000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	158684000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1538727000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1786421000	usd
CY2024Q3	gh	Revenue From Precision Oncology Testing RevenueFromPrecisionOncologyTesting	180604000	usd
CY2023Q3	gh	Revenue From Precision Oncology Testing RevenueFromPrecisionOncologyTesting	133423000	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-4139254
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3100 Hanover Street
	dei	Entity Address City Or Town EntityAddressCityOrTown	Palo Alto
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94304
	dei	City Area Code CityAreaCode	855
	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 par value per share
	dei	Trading Symbol TradingSymbol	GH
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	80647000	usd
CY2023Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	72736000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	71671000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	63475000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	29554000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	17965000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	197345000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	205917000	usd
CY2024Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1141901000	usd
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1139966000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	170131000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	185848000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	89446000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	96006000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	1598823000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1627737000	usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
	gh	Revenue From Precision Oncology Testing RevenueFromPrecisionOncologyTesting	503351000	usd
	gh	Revenue From Precision Oncology Testing RevenueFromPrecisionOncologyTesting	372060000	usd
CY2024Q3	gh	Revenue From Development Services RevenueFromDevelopmentServices	10872000	usd
CY2023Q3	gh	Revenue From Development Services RevenueFromDevelopmentServices	9607000	usd
	gh	Revenue From Development Services RevenueFromDevelopmentServices	33851000	usd
	gh	Revenue From Development Services RevenueFromDevelopmentServices	36834000	usd
CY2024Q3	us-gaap	Revenues Revenues	191476000	usd
	us-gaap	Revenues Revenues	537202000	usd
	us-gaap	Revenues Revenues	408894000	usd
CY2024Q3	gh	Costs Of Precision Oncology Testing CostsOfPrecisionOncologyTesting	66095000	usd
CY2023Q3	gh	Costs Of Precision Oncology Testing CostsOfPrecisionOncologyTesting	53648000	usd
	gh	Costs Of Precision Oncology Testing CostsOfPrecisionOncologyTesting	191116000	usd
	gh	Costs Of Precision Oncology Testing CostsOfPrecisionOncologyTesting	148111000	usd
CY2024Q3	gh	Cost Of Development Services CostOfDevelopmentServices	8394000	usd
CY2023Q3	gh	Cost Of Development Services CostOfDevelopmentServices	3966000	usd
	gh	Cost Of Development Services CostOfDevelopmentServices	21090000	usd
	gh	Cost Of Development Services CostOfDevelopmentServices	16424000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	93851000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	254210000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	277338000	usd
CY2024Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	97880000	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	68934000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	49129000	usd
CY2024Q3	us-gaap	Costs And Expenses CostsAndExpenses	308804000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	256573000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	854831000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-117328000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-113543000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	13257000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	21477000	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	646000	usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	644000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	1936000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	1933000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-47272000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	56490000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	457363000	usd
	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	usd
CY2024Q3	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2024Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2024Q3	us-gaap	Goodwill Goodwill	3290000	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	700000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1700000	usd
CY2024Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	8100000	usd
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Local Phone Number LocalPhoneNumber	698-8887
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Revenues Revenues	143030000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	87306000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.88
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.88
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2789000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-86102000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	228299000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	158684000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2597000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	7212000	usd
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	7658000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	104045000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	391000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-325367000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-60096000	usd
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	21131000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	381369000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	290000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	6697000	usd
	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	8112000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	66439000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	13842000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	228299000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-325367000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-292406000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	31933000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	32013000	usd
	gh	Non Cash Operating Lease Costs NonCashOperatingLeaseCosts	23357000	usd
	gh	Non Cash Operating Lease Costs NonCashOperatingLeaseCosts	22146000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	66439000	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-47225000	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	84513000	usd
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	0	usd
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	29054000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2372000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-334000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-316000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-8360000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10349000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	25435000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	9192000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2558000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1561000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-2280000	usd
	gh	Increase Decrease In Accounts Payable Accrued And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities	-19813000	usd
	gh	Increase Decrease In Accounts Payable Accrued And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedAndOtherLiabilities	26577000	usd
	gh	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-27029000	usd
	gh	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-22724000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	9598000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	3168000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-175345000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-246247000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	307323000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	629902000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	35000000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	828700000	usd
	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	19195000	usd
	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	0	usd
	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	2500000	usd
	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	5593000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16210000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16409000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-271838000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	176796000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2597000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	290000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	7212000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	6697000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	7658000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	8112000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	402500000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	20478000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-212000	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	5910000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1939000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	386807000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-75000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1941000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-445319000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	315415000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1133687000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	141948000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	688368000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	457363000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	585022000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	457339000	usd
CY2024Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	103346000	usd
CY2023Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	24000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	688368000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the condensed consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, estimation of credit losses, standalone selling price allocation included in contracts with multiple performance obligations, goodwill and identifiable intangible assets, stock-based compensation, incremental borrowing rate for operating leases, contingencies, certain inputs into the provision for income taxes, including related reserves, valuation of non-marketable securities, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.
CY2024Q3	us-gaap	Restricted Cash RestrictedCash	103300000	usd
CY2024Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	11100000	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	8600000	usd
	gh	Equity Security Fvni Impairment Of Purchase Rights EquitySecurityFVNIImpairmentOfPurchaseRights	22100000	usd
CY2022	gh	Equity Security Fvni Impairment Of Purchase Rights EquitySecurityFVNIImpairmentOfPurchaseRights	5300000	usd
CY2023Q2	gh	Equity Security Fvni Impairment Of Purchase Rights EquitySecurityFVNIImpairmentOfPurchaseRights	7000000	usd
	gh	Equity Security Fvni Impairment Or Adjustments To Carrying Value EquitySecurityFVNIImpairmentOrAdjustmentsToCarryingValue	0	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Concentration of Risk</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable debt securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company’s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the condensed consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invests in investment-grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company’s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after-tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable. The majority of the Company’s accounts receivable arises from the provision of precision oncology services, and development services and other, primarily with biopharmaceutical companies and international laboratory partners, all of which have high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded net of allowance for credit losses, if any.</span></div>
CY2024Q3	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	4600000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	4900000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q3	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0	usd
CY2024Q3	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	18200000	usd
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	31900000	usd
CY2023Q3	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	7400000	usd
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	12200000	usd
CY2024Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	32500000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	22900000	usd
CY2024Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	3000000.0	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	5000000.0	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	12600000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	12700000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	282089000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	272404000	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	156920000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	127308000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	125169000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	145096000	usd
CY2024Q3	us-gaap	Depreciation Depreciation	10100000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	10300000	usd
	us-gaap	Depreciation Depreciation	30200000	usd
	us-gaap	Depreciation Depreciation	29900000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	27383000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	27950000	usd
CY2024Q3	gh	Contingent Consideration Expenses ContingentConsiderationExpenses	12500000	usd
CY2023Q4	gh	Contingent Consideration Expenses ContingentConsiderationExpenses	6500000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	31788000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	29025000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	71671000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	63475000	usd
CY2024Q3	gh	Debt Securities Available For Sale And Cash And Cash Equivalents Amortized Cost DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost	923285000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	480000	usd
CY2024Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	25000	usd
CY2024Q3	gh	Cash Cash Equivalents And Debt Securities Fair Value CashCashEquivalentsAndDebtSecuritiesFairValue	923740000	usd
CY2023Q4	gh	Debt Securities Available For Sale And Cash And Cash Equivalents Amortized Cost DebtSecuritiesAvailableForSaleAndCashAndCashEquivalentsAmortizedCost	1067608000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	11000	usd
CY2023Q4	gh	Cash Cash Equivalents And Debt Securities Fair Value CashCashEquivalentsAndDebtSecuritiesFairValue	1067597000	usd
CY2023Q3	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	usd
	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	usd
	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease	0	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	18586000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	11335000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7251000	usd
CY2024Q3	us-gaap	Goodwill Goodwill	3290000	usd
CY2024Q3	gh	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	21876000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	11335000	usd
CY2024Q3	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	10541000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	18586000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9607000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	8979000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3290000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	3290000	usd
CY2023Q4	gh	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	21876000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9607000	usd
CY2023Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	12269000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2100000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	491000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1670000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1212000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1107000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1109000	usd
CY2024Q3	gh	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	1662000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7251000	usd
CY2020Q4	gh	Convertible Debt Hedge Strike Price ConvertibleDebtHedgeStrikePrice	182.60
CY2020Q4	gh	Convertible Debt Hedge Share Price Premium Percentage ConvertibleDebtHedgeSharePricePremiumPercentage	0.75
CY2020Q4	us-gaap	Share Price SharePrice	104.34
CY2020Q4	gh	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Hedges AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtHedges	90000000	usd
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	7400000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	23400000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	22100000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y8M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y3M18D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0382
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0387
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	8924000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	33733000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	29369000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	25717000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	24238000	usd
CY2024Q3	gh	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	103780000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	225761000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	28247000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	197514000	usd
	us-gaap	Dividends Common Stock DividendsCommonStock	0	usd
CY2023	us-gaap	Dividends Common Stock DividendsCommonStock	0	usd
CY2024Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	27983114	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	24715971	shares
CY2023Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	14375000	shares
CY2023Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	28.00
CY2023Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	381400000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	21100000	usd
CY2023Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3387446	shares
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	26.77
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	90600000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	12003394	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4012903	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.76
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	39115000	usd
	gh	Share Based Compensation Arrangement By Share Based Payment Award Options Annual Increase In Shares Available ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable	3689000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	478263	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	23.96
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	581495	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.47
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	166790	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	50.77
	gh	Share Based Compensation Arrangement By Share Based Payment Award Adjustments In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardAdjustmentsInPeriodGross	48234	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	15568268	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3742881	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	34.15
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	21302000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2178301	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	33.96
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y1M6D
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	20696000	usd
CY2024Q1	gh	Share Based Compensation Arrangement By Share Based Payment Award Options Annual Increase In Shares Available ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAnnualIncreaseInSharesAvailable	3689000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	19.42
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	24.42
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.35
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	22.39
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	29300000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M24D
CY2024Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	49769000	usd
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21819000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	104045000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	66439000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-107754000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-107754000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-86102000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-86102000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-325367000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-325367000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-292406000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-292406000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.88
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.88
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.66
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.66
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.66
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.66
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	123051000	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	123051000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	117736000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	117736000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	122406000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	122406000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	109791000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	109791000	shares
CY2024Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18571000	shares
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17937000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19000000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17923000	shares
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q3	us-gaap	Revenues Revenues	191476000	usd
CY2023Q3	us-gaap	Revenues Revenues	143030000	usd
	us-gaap	Revenues Revenues	537202000	usd
	us-gaap	Revenues Revenues	408894000	usd
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001576280-24-000261-index-headers.html	Edgar Link	pending
0001576280-24-000261-index.html	Edgar Link	pending
0001576280-24-000261.txt	Edgar Link	pending
0001576280-24-000261-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gh-09302024x10qxex311.htm	Edgar Link	pending
gh-09302024x10qxex312.htm	Edgar Link	pending
gh-09302024x10qxex313.htm	Edgar Link	pending
gh-09302024x10qxex321.htm	Edgar Link	pending
gh-09302024x10qxex322.htm	Edgar Link	pending
gh-09302024x10qxex323.htm	Edgar Link	pending
gh-20240930.htm	Edgar Link	pending
gh-20240930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
gh-20240930_cal.xml	Edgar Link	unprocessable
gh-20240930_def.xml	Edgar Link	unprocessable
gh-20240930_lab.xml	Edgar Link	unprocessable
gh-20240930_pre.xml	Edgar Link	unprocessable
gh-20240930_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GH
Guardant Health, Inc. Stock $gh

2024 Q4 Form 10-Q Financial Statement

#000157628024000261 Filed on November 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GH Guardant Health, Inc. Stock $gh

2024 Q4 Form 10-Q Financial Statement

#000157628024000261 Filed on November 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GH
Guardant Health, Inc. Stock $gh